Clinical trials: Hypertension,Essential
Hypertension, Vascular Diseases
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE-II (NCT03614260)
- Testing
- Paradise Renal Denervation System, Renal Angiogram
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- ReCor Medical, Inc.
Hypertension, Vascular Diseases
A Study of the ReCor Medical Paradise System in Clinical Hypertension
RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of…
- Trial name
- RADIANCE-HTN (NCT02649426)
- Testing
- The Paradise® Renal Denervation Ultrasound System
- Where
- 49 sites in United States, Belgium and 5 more
- Volunteers
- 282 people
- Sponsor
- ReCor Medical, Inc.
Hypertension,Essential, White Coat Hypertension
Implementing Hypertension Screening Guidelines in Primary Care
The goal of this study is to use a cluster-randomized design (1:1 ratio) among 8 primary care clinics affiliated with New York-Presbyterian Hospital to test the effectiveness of a theory-informed multifaceted implementation…
- Trial name
- EMBRACE (NCT03480217)
- Testing
- Multifaceted Implementation Strategy, Usual care
- Where
- 2 sites in United States
- Volunteers
- 1,186 people
- Sponsor
- Columbia University
Hypertension, Hypertension,Essential
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
- Trial name
- NCT03503773
- Testing
- Alcohol
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 350 people
- Sponsor
- Ablative Solutions, Inc.
Hypertension
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
The purpose of the study is to evaluate the efficacy and safety of the study drug relative to an active comparator losartan which is in the same class of drug and is approved for use in the pediatric population aged 6 years and…
- Trial name
- NCT02235909
- Testing
- Azilsartan Medoxomil Low-dose, Losartan, Azilsartan Medoxomil Medium-dose (20 mg)
- Where
- 69 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Hypertension, Renal
RENABLATE Feasibility Study CS156 (EC12-02) Study of Catheter Based Renal Denervation to Treat Resistant Hypertension
The RENABLATE feasibility study is a prospective, multi-center, non-randomized feasibility study to evaluate the safety and effectiveness of the investigational multi-electrode ablation catheter and integrated ablation system to…
- Trial name
- NCT01756300
- Testing
- Celsius® ThermoCool® RD
- Volunteers
- 35 people
- Sponsor
- Biosense Webster, Inc.
Hypertension
Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)
This study will determine whether using losartan and amlodipine together will be non-inferior in lowering blood pressure than amlodipine alone.
- Trial name
- NCT01277822
- Testing
- Losartan (+) amlodipine, Amlodipine camsylate
- Volunteers
- 334 people
- Sponsor
- Organon and Co
Hypertension
A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).
- Trial name
- NCT01307033
- Testing
- MK-0954A, MK-954H
- Volunteers
- 278 people
- Sponsor
- Organon and Co
Hypertension
MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)
This study is being conducted to evaluate the efficacy of MK-0954A in essential hypertension participants who are not adequately controlled with losartan.
- Trial name
- NCT01307046
- Testing
- MK-0954A, Losartan
- Volunteers
- 336 people
- Sponsor
- Organon and Co
Hypertension,Essential
Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans
High blood pressure can cause physical changes to the blood vessels of the body (remodeling). If a person who has high blood pressure also has a lot of blood vessel remodeling with their condition, they are more likely to have…
- Trial name
- H2SPharm (NCT03179163)
- Testing
- Captopril Pill, Enalapril Pill, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Penn State University
Hypertension, Blood Pressure
HIRREM for Stage 1 Primary Hypertension
The purpose of this study is to determine that effects of an intervention called High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM), on Stage 1 Primary Hypertension (systolic BP 130-139, and/or…
- Conditions
- Hypertension, Blood Pressure, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- HIRREM (NCT03479697)
- Testing
- HIRREM, Continued Current Care
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Essential Hypertension
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
- Trial name
- NCT02603809
- Testing
- Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg
- Where
- 90 sites in United States, Canada and 2 more
- Volunteers
- 1,659 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Essential Hypertension
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies…
- Trial name
- NCT03514641
- Testing
- Bexagliflozin
- Where
- 87 sites in United States
- Volunteers
- 673 people
- Sponsor
- Theracos
Essential Hypertension
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of…
- Trial name
- NCT00758524
- Testing
- LCI699, Eplerenone
- Where
- United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
This study tested the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in participants with essential hypertension.
- Trial name
- NCT00667719
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 564 people
- Sponsor
- Novartis
Essential Hypertension
FimasaRtan-basEd BP Targets After Drug SwitcHing
The recent hypertension clinical practice guidelines published by American College of Cardiology (ACC) and American Heart Association (AHA) reduced the target BP to 130/80 mmHg, indicating the needs for more aggressive efforts in…
- Trial name
- FRESH (NCT03649646)
- Where
- South Korea
- Volunteers
- 4,542 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Safety Study of RMJH-111b to Treat Essential Hypertension
The purpose of this study was to evaluate the safety of RMJH-111b, including how well it is tolerated, and the effect of RMJH-111b on blood pressure in subjects with hypertension.
- Trial name
- NCT02822222
- Testing
- Magnesium citrate, tribasic anhydrous soft gelatin capsule
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RMJ Holdings, LLC
Essential Hypertension ( Mild to Moderate)
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension.
- Trial name
- NCT00765947
- Testing
- Aliskiren, Hydrochlorothiazide, Amlodipine
- Where
- 4 sites in France, Hungary and 2 more
- Volunteers
- 256 people
- Sponsor
- Novartis
Primary Hypertension
A Study of LY2623091 in Participants With High Blood Pressure
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
- Trial name
- NCT02194465
- Testing
- LY2623091, Tadalafil, Spironolactone
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Hypertension
MK-0954E Study in Participants With Hypertension (MK-0954E-357)
This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E).
- Trial name
- NCT01302691
- Testing
- losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E), Losartan potassium, Amlodipine besylate
- Volunteers
- 327 people
- Sponsor
- Merck Sharp & Dohme LLC